Eisai and Biogen’s new Alzheimer’s drug Leqembi could cost Medicare an estimated $2 billion to $5 billion annually, according to a study published May 11 in JAMA Internal Medicine.
Read the full post on Becker's Hospital Review - Healthcare News
Alzheimer's drug may cost Medicare $5B annually, study estimates
